In a patient with fever, cytopenias and markedly elevated ferritin being evaluated for hemophagocytic lymphohistiocytosis, what is the significance of an eosinophil count of 8 % and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Eosinophilia in HLH: Significance and Management

An eosinophil count of 8% in a patient being evaluated for HLH should prompt immediate consideration of DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) as an alternative or overlapping diagnosis, particularly if there is recent drug exposure within the past 2-4 weeks.

Clinical Significance of Eosinophilia

  • Eosinophilia is NOT a typical feature of HLH and should redirect your diagnostic thinking 1
  • The HLH-2004 diagnostic criteria specifically list cytopenias affecting ≥2 of 3 lineages (hemoglobin <90 g/L, platelets <100 × 10⁹/L, neutrophils <1.0 × 10⁹/L) as diagnostic features—eosinophilia is conspicuously absent 1, 2
  • When eosinophilia (8%) coexists with fever, cytopenias, and elevated ferritin, DRESS syndrome with secondary HLH becomes the leading diagnostic consideration 3

DRESS-HLH Overlap Syndrome

  • 61% of patients with DRESS-HLH overlap initially worsen despite standard DRESS therapy, with HLH diagnosed an average of 2.3 weeks after the initial DRESS diagnosis 3
  • The most predictive clinical pattern for dual DRESS-HLH diagnosis includes: fever, generalized rash, bicytopenia, internal organ involvement, and recent drug exposure (average onset 2.7 weeks post-exposure) 3
  • Patients presenting with this overlap pattern who are treated with steroid monotherapy and develop viral reactivation have the poorest outcomes 3

Immediate Diagnostic Workup Required

Confirm or Exclude DRESS

  • Obtain detailed medication history for the past 4-6 weeks, focusing on anticonvulsants, allopurinol, sulfonamides, and antibiotics 3
  • Look for characteristic rash (morbilliform eruption with facial edema) 3
  • Calculate RegiSCAR score if DRESS is suspected 3
  • Check for viral reactivation (EBV, CMV, HHV-6) which occurs in both DRESS and HLH 3, 4

Complete HLH Evaluation

  • Verify that 5 of 8 HLH-2004 criteria are met (fever, splenomegaly, cytopenias ≥2 lineages, hypertriglyceridemia/hypofibrinogenemia, hemophagocytosis, low NK cell activity, ferritin ≥500 mg/L, sCD25 ≥2400 U/mL) 1, 2
  • Obtain sCD25 level immediately—it outperforms ferritin with AUC 0.90 vs 0.78 and should not delay treatment 5
  • Ferritin >10,000 mg/L is 90% sensitive and 96% specific for HLH in children; in adults, levels >7,000-10,000 mg/L strongly suggest HLH 1, 6
  • Bone marrow examination for hemophagocytosis is supportive but not required if other criteria are met 7

Management Algorithm

If DRESS-HLH Overlap is Confirmed

Immediate interventions:

  • Discontinue all potentially offending medications 3
  • Initiate high-dose systemic corticosteroids (dexamethasone preferred over prednisone for HLH component) 5, 3
  • Do NOT use steroid monotherapy—add etoposide and cyclosporine A per HLH-2004 protocol if ≥5 HLH criteria are met 5, 3
  • Consider IVIG or plasmapheresis as adjunctive therapy 3
  • Monitor closely for viral reactivation (EBV, CMV, HHV-6) which predicts poor outcomes 3

If Pure HLH Without DRESS Features

  • Initiate HLH-2004 protocol: dexamethasone + etoposide + cyclosporine A 5
  • Aggressively search for underlying triggers: malignancy (T-cell/NK-cell lymphomas 35%, B-cell lymphomas 32%), infections (EBV, CMV), autoimmune disorders 1, 5
  • Continue trigger search even during ongoing HLH treatment—occult malignancies require meticulous evaluation 1

Critical Pitfalls to Avoid

  • Do not dismiss HLH diagnosis solely because eosinophils are elevated—DRESS-HLH overlap exists and requires dual treatment 3
  • Do not delay HLH-directed therapy while awaiting bone marrow results or sCD25 levels if clinical suspicion is high 5, 7
  • Do not use steroid monotherapy in DRESS-HLH overlap—this approach is associated with poor outcomes and viral reactivation 3
  • Do not stop at 4 fulfilled HLH criteria if hemophagocytosis is absent—ferritin >10,000 mg/L with appropriate clinical context warrants treatment 7, 6
  • Hyperferritinemia is less specific in adults than children; integrate all clinical features rather than relying on ferritin alone 1, 8

Monitoring Parameters

  • Serial sCD25 and ferritin levels to assess treatment response 5
  • Platelet count every 12-24 hours alongside temperature, spleen size, and liver enzymes 5
  • Repeat viral PCR studies (EBV, CMV, HHV-6) to detect reactivation 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.